Soften the Lines
Without Breaking the Budget

Letybo (letibotulinumtoxinA-wlbg) is a botulinum toxin type A injectable for wrinkle relaxation, in the same drug class as Botox and Dysport. The FDA approved it in February 2024 for the temporary improvement of moderate to severe glabellar lines, the vertical lines between the brows that show up when you frown, squint, or concentrate.

Letybo is manufactured by Hugel, Inc., a South Korean pharmaceutical company that had already been selling botulinum toxin products in Asian and European markets before Letybo reached FDA approval in the US. At New Day Medspa, it's injected by licensed, medically trained aesthetic providers who treat frown lines every day and know how to dose for a result that reads as rested, not done.

Letybo blocks the nerve signals that tell your corrugator and procerus muscles, the small muscles between your brows, to contract. Less muscle movement means the skin above it stops folding into a crease every time you frown.

Letybo's FDA approval was supported by clinical trials involving more than 1,270 patients. Across those trials, patients generally saw noticeable softening within 2 to 3 days, with full effect settling in over the following 2 to 4 weeks. Results typically lasted 16 weeks. Letybo shouldn't be re-injected more often than every 3 months, which lines up with how long most patients see it last anyway.

Letybo is a more budget friendly alternative to other wrinkle relaxer brands, with pricing as low as $9.99 per unit. It is now New Day Medspa's most popular wrinkle relaxer option.